About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio-5.57142857142857
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-38.60%
Return on Assets-25.48%
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions
What is Navidea Biopharmaceuticals' stock symbol?
Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
How were Navidea Biopharmaceuticals' earnings last quarter?
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.22 million for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 38.60% and a negative net margin of 688.85%. View Navidea Biopharmaceuticals' Earnings History.
Are investors shorting Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 4,593,961 shares, an increase of 0.2% from the February 15th total of 4,586,268 shares. Based on an average daily volume of 183,400 shares, the short-interest ratio is currently 25.0 days. Approximately 3.0% of the company's shares are sold short.
Who are some of Navidea Biopharmaceuticals' key competitors?
Some companies that are related to Navidea Biopharmaceuticals include Bioventix (BVXP), Asterias Biotherapeutics (AST), Tissue Regenix Group (TRX), Matinas BioPharma (MTNB), NovaBay Pharmaceuticals (NBY), Abzena (ABZA), Scancell (SCLP), Can Fite Biopharma (CANF), ReNeuron Group (RENE), Repros Therapeutics (RPRX), Akers Biosciences (AKR), AmpliPhi Biosciences (APHB), Synairgen (SNG), Vernalis (VER), Ixico (IXI), ImmunoCellular Therapeutics (IMUC), Sorrento Tech (ROKA) and Celator Pharmaceuticals (CPXX).
Who are Navidea Biopharmaceuticals' key executives?
Navidea Biopharmaceuticals' management team includes the folowing people:
- Eric K. Rowinsky M.D., Chairman of the Board (Age 60)
- Michael M. Goldberg M.D., President, Chief Executive Officer, Director (Age 57)
- Jed A Latkin, Chief Financial Officer, Interim Chief Operating Officer, Chief Accounting Officer (Age 41)
- Frederick O. Cope Ph.D., Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer (Age 69)
- William J. Regan, Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer (Age 63)
- Claudine Bruck, Director
- Mark I. Greene M.D. Ph.D., Director (Age 67)
- Michael Rice, Director (Age 51)
Has Navidea Biopharmaceuticals been receiving favorable news coverage?
Media stories about NAVB stock have trended positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Navidea Biopharmaceuticals earned a media sentiment score of 0.28 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Navidea Biopharmaceuticals' major shareholders?
Navidea Biopharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sowell Financial Services LLC (0.31%). Company insiders that own Navidea Biopharmaceuticals stock include Jed Latkin and William J Regan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.
Which major investors are selling Navidea Biopharmaceuticals stock?
How do I buy shares of Navidea Biopharmaceuticals?
Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Navidea Biopharmaceuticals' stock price today?
One share of NAVB stock can currently be purchased for approximately $0.39.
How big of a company is Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals has a market capitalization of $62.36 million.
How can I contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.
MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings History and Estimates Chart
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.01)||$0.22 million||View||N/A|
|8/8/2017||Q2 2017||($0.02)||$0.61 million||View||Listen|
|5/9/2017||Q1 2017||($0.01)||$0.58 million||View||N/A|
|3/29/2017||Q4 2016||($0.02)||$3.36 million||View||N/A|
|8/4/2016||Q216||($0.03)||($0.04)||$5.24 million||$5.40 million||View||N/A|
|5/17/2016||Q1||($0.03)||($0.02)||$4.63 million||$4.70 million||View||Listen|
|3/23/2016||Q415||($0.04)||($0.02)||$3.70 million||$4.00 million||View||Listen|
|11/4/2015||Q315||($0.04)||($0.05)||$2.40 million||$3.98 million||View||Listen|
|7/30/2015||Q215||($0.04)||($0.06)||$2.18 million||$2.90 million||View||Listen|
|5/12/2015||Q115||($0.03)||($0.05)||$3.30 million||$2.10 million||View||Listen|
|3/5/2015||($0.04)||($0.05)||$1.95 million||$2.20 million||View||N/A|
|3/5/2015||($0.04)||($0.05)||$1.95 million||$2.20 million||View||N/A|
|3/5/2015||Q414||($0.05)||($0.05)||$2.10 million||$2.20 million||View||Listen|
|11/6/2014||Q314||($0.06)||($0.05)||$1.54 million||$2.30 million||View||Listen|
|8/6/2014||Q214||($0.07)||($0.07)||$1.05 million||$1.05 million||View||Listen|
|5/7/2014||Q114||($0.10)||($0.06)||$0.90 million||$0.75 million||View||Listen|
|3/6/2014||Q413||($0.08)||($0.10)||$0.74 million||$0.54 million||View||Listen|
|11/6/2013||Q313||($0.08)||$0.09||$0.97 million||$0.40 million||View||Listen|
|8/7/2013||Q2 2013||($0.07)||($0.09)||$0.55 million||$0.20 million||View||N/A|
|5/8/2013||Q1 2013||($0.07)||($0.06)||$0.02 million||View||N/A|
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
No dividend announcements for this company have been tracked by MarketBeat.com
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading and Institutional Ownership History
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/29/2017||William J Regan||SVP||Buy||20,000||$0.53||$10,600.00||172,977|| |
|5/30/2017||Jed Latkin||CFO||Buy||7,600||$0.44||$3,344.00||50,159|| |
|5/22/2017||Jed Latkin||CFO||Buy||25,359||$0.45||$11,411.55||31,359|| |
|12/1/2015||Brent L Larson||CFO||Sell||12,500||$1.50||$18,750.00||222,237|| |
|10/1/2015||Brent L Larson||CFO||Sell||12,500||$2.27||$28,375.00||247,237|| |
|9/1/2015||Brent L Larson||CFO||Sell||12,500||$1.88||$23,500.00||259,737|| |
|6/1/2015||Brent L Larson||CFO||Sell||12,500||$1.24||$15,500.00|| |
|5/29/2015||Gordon A Troup||Director||Buy||10,000||$1.31||$13,100.00|| |
|11/14/2014||Michael M Goldberg||Director||Buy||100,000||$1.08||$108,000.00|| |
|11/10/2014||Brendan A Ford||Director||Buy||10,000||$1.03||$10,300.00|| |
|5/9/2014||Mark Jerome Pykett||CEO||Buy||10,000||$1.34||$13,400.00||292,674|| |
|3/10/2014||Brent Larson||CFO||Sell||41,500||$1.96||$81,340.00||319,184|| |
|3/10/2014||Frederick Cope||SVP||Sell||15,000||$1.96||$29,400.00||75,814|| |
|3/10/2014||Mark Jerome Pykett||CEO||Sell||120,000||$1.96||$235,200.00||282,674|| |
|11/8/2013||Brendan Ford||Director||Buy||20,000||$1.45||$29,000.00||139,250|| |
|11/8/2013||Brent Larson||CFO||Buy||5,000||$1.39||$6,950.00||287,304|| |
|11/8/2013||Frederick Cope||SVP||Buy||3,500||$1.43||$5,005.00||90,814|| |
|11/8/2013||Mark Jerome Pykett||CEO||Buy||10,900||$1.35||$14,715.00||402,674|| |
|3/15/2013||Gordon A Troup||Director||Buy||7,000||$2.70||$18,900.00|| |
|3/15/2013||Mark Jerome Pykett||CEO||Buy||1,850||$2.70||$4,995.00|| |
|3/15/2013||Thomas H Tulip||EVP||Buy||17,500||$2.82||$49,350.00|| |
|3/15/2013||William J Regan||SVP||Buy||5,000||$2.71||$13,550.00|| |
|9/14/2012||Thomas H Tulip||EVP||Buy||15,000||$2.70||$40,500.00|| |
|9/12/2012||Brendan A Ford||Director||Buy||5,000||$2.64||$13,200.00|| |
|9/11/2012||Mark Jerome Pykett||CEO||Buy||4,000||$2.64||$10,560.00|| |
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) News Headlines
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Income Statement, Balance Sheet and Cash Flow Statement
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Stock Chart for Monday, March, 19, 2018